ta-8995
Small moleculeexperimental
Clinical trial activity
9 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2008 (NCT01878474)
Timeline
Indications
Mechanism of action
- Cholesteryl ester transfer proteinINHIBITOR
CETP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ta-8995
- ta-8995
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04770389 | Phase 2 | Feb 23, 2021 | NewAmsterdam Pharma |
| NCT02523391 | Phase 1 | Jul 1, 2015 | Xention Ltd |
| NCT02408055 | Phase 1 | Jun 1, 2015 | Covance, Xention Ltd |
| NCT02241772 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2014 | Xention Ltd |
| NCT02241759 | Phase 1 | Aug 1, 2014 | Covance, Xention Ltd |
| NCT02124954 | Phase 1 | May 1, 2014 | Covance, Xention Ltd |
| NCT01970215 | Phase 2 | Aug 1, 2013 | Xention Ltd |
| NCT01879020 | Phase 1 | Aug 1, 2009 | Mitsubishi Tanabe, Momentum Research, Inc. |
| NCT01878474 | Phase 1 | Mar 1, 2008 | Hammersmith Medicines Research, Mitsubishi Tanabe |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xention Ltd | For profit | 6 | 6 | 2 | 2013 |
| Covance | For profit | 3 | 0 | 1 | 2014 |
| Mitsubishi Tanabe | For profit | 2 | 2 | 1 | 2008 |
| Hammersmith Medicines Research | For profit | 1 | 0 | 1 | 2008 |
| Momentum Research, Inc. | For profit | 1 | 0 | 1 | 2009 |
| NewAmsterdam Pharma | For profit | 1 | 1 | 1 | 2021 |
6 organizations
Page 1 / 1